mage-k1 Activators
MAGE-K1 Activators represent a diverse group of compounds that indirectly augment the functional activity of MAGE-K1, primarily by modulating the nuclear transcriptional environment. Histone deacetylase inhibitors like Trichostatin A and Vorinostat, along with the short-chain fatty acid Sodium Butyrate, play a crucial role in remodeling chromatin architecture. This remodeling enhances the access of MAGE-K1 to transcriptional complexes, thereby facilitating its role in negatively regulating transcription by RNA polymerase II. Similarly, 5-Azacytidine and JQ1, by altering DNA methylation patterns and modulating the activity of bromodomain-containing proteins respectively, create a more conducive environment for MAGE-K1 to exercise its regulatory functions. The proteasome inhibitor MG132 contributes to this regulation by stabilizing proteins within MAGE-K1's interaction network, thus enhancing its regulatory impact.
Furthermore, the activity of MAGE-K1 is intricately linked to various signaling pathways that converge on the nucleus. Lithium Chloride's influence on the Wnt signaling pathway, LY294002's inhibition of PI3K, and Rapamycin's modulation of mTOR pathways exemplify how altering upstream signaling cascades can indirectly affect the transcriptional regulatory functions of MAGE-K1. Additionally, compounds like SB203580, U0126, and PD98059, which target the MAPK pathway through the inhibition of p38, MEK, and MEK1/2 respectively, play a significant role. By modulating these pathways, these compounds indirectly influence the nuclear transcriptional regulation activities where MAGE-K1 is active, thereby enhancing its functional role in the negative regulation of transcription by RNA polymerase II. Collectively, these MAGE-K1 Activators, through their targeted effects on cellular signaling and nuclear transcriptional processes, facilitate the enhancement of MAGE-K1's role in transcriptional regulation without the need for upregulating its expression or direct activation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, can enhance the nuclear function of MAGE-K1 by promoting chromatin remodeling. This facilitates MAGE-K1's interaction with transcriptional regulators in the nucleus, indirectly enhancing its role in the negative regulation of transcription by RNA polymerase II. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, indirectly enhances MAGE-K1 activity by altering the methylation status of DNA. This leads to changes in gene expression patterns, which can include genes that interact with or regulate MAGE-K1, thereby modulating its function in transcriptional regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat, another histone deacetylase inhibitor, functions similarly to Trichostatin A by facilitating chromatin decondensation. This can enhance MAGE-K1's access to transcriptional complexes and its ability to regulate transcription in the nucleus. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132, a proteasome inhibitor, can indirectly affect MAGE-K1 function by stabilizing proteins that interact with MAGE-K1 or are part of its regulatory network, thus influencing its role in transcriptional regulation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium Chloride, which influences the Wnt signaling pathway, can indirectly affect MAGE-K1 activity by modulating the transcriptional regulation of genes involved in this pathway, potentially impacting MAGE-K1's role in the nucleus. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, by altering AKT signaling, can indirectly influence MAGE-K1's role in transcriptional regulation, as changes in AKT signaling may affect nuclear processes where MAGE-K1 is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, can indirectly enhance MAGE-K1's function by modulating cellular stress responses, which may impact nuclear transcriptional regulation activities where MAGE-K1 participates. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, a MEK inhibitor, can influence ERK/MAPK pathway signaling, potentially altering the transcriptional regulatory network in which MAGE-K1 is involved, thereby modulating its function in the nucleus. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, by altering cell growth and survival pathways, can indirectly impact the transcriptional regulatory functions of MAGE-K1 in the nucleus. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, an inhibitor of MEK1/2, can affect ERK/MAPK signaling, thereby potentially influencing transcriptional regulation processes in the nucleus where MAGE-K1 is active. | ||||||